Background: The effect of long-term treatment with ritonavir-boosted atazanavir (ATV/r) on cholelithiasis formation is unknown. Methodology: A single-center, cross-sectional study was conducted to elucidate the prevalence of cholelithiasis in patients with HIV-1 infection who underwent abdominal ultrasonography between January 2004 and March 2012. Uni- and multi-variate logistic regression analyses were applied to estimate the effects of >2 years of ATV/r exposure on cholelithiasis as the primary exposure. Results: Of the 890 study patients, 84 (9.4%) had >2 years of ATV/r exposure. Cholelithiasis was twice more frequently diagnosed in those treated for >2 years with ATV/r [15 (18%) of 84 patients] than in those treated for <2 years [72 (8.9%) of 806 patients] (p=0.018). Univariate analysis showed a significant association between >2 years of ATV/r exposure and cholelithiasis (OR=2.216; 95%CI, 1.206-4.073; p=0.010), and the association almost persisted in multivariate analysis (adjusted OR= 1.806; 95%CI, 0.922-3.537; p=0.085). Treatment for >2 years with ritonavir-boosted lopinavir (LPV/r) and ritonavir-boosted darunavir (DRV/r) was not associated with cholelithiasis in uni- and multi-variate analysis { >2 years exposure to LPV/r [n=148 (16.6%)]: OR 1.246, 95% CI 0.710-2.185, p=0.443; adjusted OR 1.221, 95% CI 0.674-2.214, p=0.510} { >2 years exposure to DRV/r [n=29 (3.3%)]: OR 1.067, 95% CI 0.316-3.601, p=0.916; adjusted OR 0.641, 95% CI 0.173-2.377, p=0.506}. Additional analysis showed that >1 year exposure to ATV/r [n=124 (13.9 %)] was significantly associated with cholelithiasis (OR 1.857, 95%CI 1.073-3.214, p=0.027), whereas >1 year exposure to LPV/r and DRV/r was not. Conclusions: Long-term treatment of patients with HIV-1 infection for >2 years with ATV/r was associated with increased risk for cholelithiasis compared to patients with shorter exposure. Long-term exposure to ATV/r appears to increase the risk of cholelithiasis in patients with HIV-1 infection.